JP2759305B2 - Medical tubing - Google Patents
Medical tubingInfo
- Publication number
- JP2759305B2 JP2759305B2 JP4084702A JP8470292A JP2759305B2 JP 2759305 B2 JP2759305 B2 JP 2759305B2 JP 4084702 A JP4084702 A JP 4084702A JP 8470292 A JP8470292 A JP 8470292A JP 2759305 B2 JP2759305 B2 JP 2759305B2
- Authority
- JP
- Japan
- Prior art keywords
- medical tube
- polyurethane
- body temperature
- catheter
- cannula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000036760 body temperature Effects 0.000 claims description 19
- 229920002635 polyurethane Polymers 0.000 claims description 13
- 239000004814 polyurethane Substances 0.000 claims description 13
- 229920000620 organic polymer Polymers 0.000 claims description 12
- 229920005862 polyol Polymers 0.000 claims description 10
- 150000003077 polyols Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000004970 Chain extender Substances 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000012948 isocyanate Substances 0.000 claims description 8
- 150000002513 isocyanates Chemical class 0.000 claims description 8
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000005038 ethylene vinyl acetate Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 6
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229920002050 silicone resin Polymers 0.000 description 5
- -1 aliphatic amines Chemical class 0.000 description 4
- 229940106691 bisphenol a Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 206010033372 Pain and discomfort Diseases 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 2
- VOZKAJLKRJDJLL-UHFFFAOYSA-N tolylenediamine group Chemical group CC1=C(C=C(C=C1)N)N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VGHSXKTVMPXHNG-UHFFFAOYSA-N 1,3-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC(N=C=O)=C1 VGHSXKTVMPXHNG-UHFFFAOYSA-N 0.000 description 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 1
- CVFRFSNPBJUQMG-UHFFFAOYSA-N 2,3-bis(2-hydroxyethyl)benzene-1,4-diol Chemical compound OCCC1=C(O)C=CC(O)=C1CCO CVFRFSNPBJUQMG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- QORUGOXNWQUALA-UHFFFAOYSA-N N=C=O.N=C=O.N=C=O.C1=CC=C(C(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 Chemical compound N=C=O.N=C=O.N=C=O.C1=CC=C(C(C2=CC=CC=C2)C2=CC=CC=C2)C=C1 QORUGOXNWQUALA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- TXXWBTOATXBWDR-UHFFFAOYSA-N n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound CN(C)CCCCCCN(C)C TXXWBTOATXBWDR-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920005906 polyester polyol Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 229920001228 polyisocyanate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000013151 thrombectomy Methods 0.000 description 1
- 239000012974 tin catalyst Substances 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
- Materials For Medical Uses (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、動物、特に人の体内に
液体等を導入、または体内から液体等を導出するために
使用される導管、さらには血管拡張、血栓・塞栓の除去
のために使用されるチューブ、人工血管、人工気管等、
即ち疾病等の検査、観測、予防、治療等の目的に用いら
れるカテーテル(catheter)、カニューレ(cannula)、
ブジー(bougie)その他の医療用チューブに関するもので
ある。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a conduit used for introducing a liquid or the like into or out of an animal, especially a human body, and for dilating a blood vessel, removing a thrombus or emboli. Tubes, artificial blood vessels, artificial trachea, etc. used for
That is, catheters, cannula, cannula, used for the purpose of inspection, observation, prevention, treatment, etc. of diseases and the like.
It relates to bougies and other medical tubes.
【0002】[0002]
【従来の技術・発明が解決しようとする課題】たとえ
ば、医療用チューブは血管(特に冠状動脈)、気管、卵
管、尿管等や各種臓器内に挿入され、液体の注入、吸
入、或いは通路の開存確保等を目的として使用される。
最近のカテーテルは、医療技術の進歩に伴い、上記通常
の機能の他に、内視のための照明用ファイバやイメージ
ガイド、更にはフラッシュ孔付のものまであり、多機能
化している。米国特許第 4,846,812号明細書には、形状
記憶性の樹脂を用いたカニューレが提案されている。2. Description of the Related Art For example, medical tubes are inserted into blood vessels (particularly coronary arteries), trachea, fallopian tubes, ureters, and various other organs to inject, inhale, or channel liquids. It is used for the purpose of ensuring patency.
Recent catheters have become multifunctional with the progress of medical technology, in addition to the above-mentioned normal functions, including illumination fibers and image guides for endoscopes, and even those with flash holes. U.S. Pat. No. 4,846,812 proposes a cannula using a shape memory resin.
【0003】ところで、医療用チューブを身体内に挿
入、留置あるいは除去する際に、不快な気持ちになった
り、場合によっては痛みや苦しみを伴う(以下本発明に
おいては、この様な不快感や身体上の状況を違和感なる
用語にて総称する)ことが多い。しかしながら、従来の
医療用チューブにおいては、この違和感については特に
問題視されておらず、当然違和感に対する配慮が殆どな
されていないのが実情である。前記米国特許明細書に開
示のカニューレにおいても、この点については、全く配
慮がなされていない。それどころか、前記米国特許明細
書に開示のカニューレは、内層を疏水性樹脂で構成する
二層構造のチューブとすることによって体液による膨潤
を緩和しているものの、その構成材料が高親水性である
ため、体内挿入後、血液等との接触による膨潤を防ぐこ
とができず、違和感を増大させるという重大な欠点を有
するものである。このような違和感は、医療用チューブ
を体内に留置することによる身体的束縛と相まって、肉
体的、精神的苦痛となりかねない。[0003] By the way, when a medical tube is inserted, placed, or removed from the body, the patient feels uncomfortable, and in some cases, suffers from pain or suffering. The above situations are collectively referred to as uncomfortable terms). However, in the conventional medical tubes, this discomfort is not particularly regarded as a problem, and the fact is that little consideration has been given to the discomfort. No consideration has been given to this point in the cannula disclosed in the above-mentioned U.S. Patent Specification. On the contrary, the cannula disclosed in the above-mentioned U.S. Patent Specification has a two-layered tube composed of a hydrophobic resin for the inner layer to alleviate swelling due to body fluid, but the constituent material is highly hydrophilic. However, after insertion into the body, it cannot prevent swelling due to contact with blood or the like, and has a serious drawback of increasing discomfort. Such uncomfortable feeling, coupled with the physical restraint caused by placing the medical tube in the body, may cause physical and mental distress.
【0004】また最近、経腸栄養(Enteral Diet)カテ
ーテル(EDカテーテル)が注目されている。EDカテ
ーテルは、成分栄養、経腸栄養、流動食の投与を目的と
して、口または鼻から喉、食道、胃を経由して、十二指
腸に留置するものである。現在EDカテーテルとしては
EVA製またはシリコン樹脂製のものが使用されている
が、EVA製は硬すぎるために挿入容易ではあるが、痛
み、違和感が強い。また、シリコン樹脂製は柔らかすぎ
て挿入困難である。従って、挿入が容易であると共に、
挿入時および留置時に痛み、違和感の少ないEDカテー
テルが待望されている。Recently, an enteral diet catheter (ED catheter) has attracted attention. The ED catheter is placed in the duodenum from the mouth or nose via the throat, esophagus, and stomach for the purpose of component nutrition, enteral nutrition, and administration of liquid food. At present, ED catheters made of EVA or silicone resin are used. EVA catheters are too hard to insert easily because they are too hard, but have a strong pain and discomfort. In addition, silicone resin is too soft and difficult to insert. Therefore, while being easy to insert,
There is a long-awaited need for an ED catheter that has less pain and discomfort during insertion and placement.
【0005】本発明の目的は、身体内への挿入が容易で
あり、しかも身体内に留置或いは身体内から除去する際
に、痛みおよび違和感の少ない医療用チューブを提供す
ることである。[0005] It is an object of the present invention to provide a medical tube which is easy to insert into a body and has little pain and uncomfortable feeling when placed in or removed from the body.
【0006】[0006]
【課題を解決するための手段】本発明者らは上記目的を
達成すべく種々検討を重ねてきたところ、下記の特定の
機械的損失正接および横弾性率を有する有機高分子より
なる医療用チューブがこれらを全て満足することを見出
した。また、挿入用チューブの吸水率を特定の範囲とす
ることにより、違和感がより一層改善されることを見出
したものである。Means for Solving the Problems The present inventors have made various studies to achieve the above object, and found that a medical tube made of an organic polymer having the following specific mechanical loss tangent and transverse elastic modulus. Found that these were all satisfied. Further, they have found that the discomfort is further improved by setting the water absorption of the insertion tube to a specific range.
【0007】即ち、本発明に係る医療用チューブは、体
温における機械的損失正接が少なくとも0.5でかつ体
温における横弾性率が1〜1000MPaである有機高
分子よりなることを特徴とするものであり、さらに好ま
しい態様は、該有機高分子の体温における吸水率が5重
量%以下であることを特徴とするものである。That is, the medical tube according to the present invention is characterized by comprising an organic polymer having a mechanical loss tangent at body temperature of at least 0.5 and a transverse elastic modulus at body temperature of 1 to 1000 MPa. In a more preferred embodiment, the organic polymer has a water absorption at a body temperature of 5% by weight or less.
【0008】本発明において、医療用チューブとは検
査、観測、診断、治療・予防或いはその他の目的でヒト
を含む動物体内に挿入して用いる全てのチューブ状医療
器(たとえば、カテーテル、カニューレ、イルリガート
ル、ブジー等)のことである。即ち、該チューブは、特
定の有機高分子からなり液注入・排出機能、体温測定機
能、血圧・血液測定機能、化学分析機能、内視機能、レ
ーザファイバやバルーン等の機能を搭載したもの等、循
環器系、呼吸器系、消化器系、泌尿器系、生殖器系等の
適用領域や使用目的・機能により多種多様にわたる。[0008] In the present invention, a medical tube refers to any tube-shaped medical device (eg, catheter, cannula, irrigator) used by being inserted into an animal body including a human for inspection, observation, diagnosis, treatment / prevention or other purposes. , Bougies, etc.). That is, the tube is made of a specific organic polymer, a liquid injecting / discharging function, a body temperature measuring function, a blood pressure / blood measuring function, a chemical analyzing function, an endoscopic function, a function equipped with a laser fiber or a balloon, etc. It varies widely depending on the application area and the purpose and function of the circulatory system, respiratory system, digestive system, urinary system, reproductive system, etc.
【0009】医療用チューブとしては、具体的には静脈
留置カテーテル、心臓カテーテル、血管造影用カテーテ
ル、血管拡張用カテーテル、血栓除去用カテーテル、胆
管カテーテル、気管支チューブ、胃管カテーテル、硬膜
外カテーテル、食道ブジー、中心静脈カテーテル、排液
用チューブ、膵管チューブ、子宮頸管留置カテーテル、
内視鏡用カテーテル、導尿用カテーテル、経鼻酸素カテ
ーテル、吸引カテーテル、套管針カテーテル、EDカテ
ーテル、輸液用チューブ等が例示される。Specific examples of the medical tube include a venous indwelling catheter, a heart catheter, an angiographic catheter, a vascular dilatation catheter, a thrombectomy catheter, a bile duct catheter, a bronchial tube, a gastric tube catheter, an epidural catheter, Esophageal bougie, central venous catheter, drainage tube, pancreatic duct tube, cervical indwelling catheter,
Examples include endoscope catheters, urinary catheters, nasal oxygen catheters, suction catheters, trocar catheters, ED catheters, infusion tubes, and the like.
【0010】また、当該チューブは人間を始めとする哺
乳動物(たとえば、ウシ、ウサギ、ウマ、ヒツジ、サ
ル、イヌ、ネコ等)等に使用可能である。従って、本発
明における体温とは、これら動物の各々の体温を意味
し、動物種によりその温度は異なる。[0010] The tube can be used for mammals including humans (for example, cows, rabbits, horses, sheep, monkeys, dogs, cats, etc.). Therefore, the body temperature in the present invention means the body temperature of each of these animals, and the temperature differs depending on the animal species.
【0011】本発明の医療用チューブを構成する有機高
分子は、体温(T℃)における機械的損失正接(tan
δT ) が少なくとも0.5、好ましくは少なくとも1.
0、より好ましくは少なくとも2.0のものである。t
anδT が、0.5未満である場合、硬すぎるために体
内挿入状態において常に周囲の組織にツッパリ感を与
え、即ち違和感を生ぜしめ、またその部分の筋肉を動か
した時、痛みを伴う場合すらあるためである。The organic polymer constituting the medical tube of the present invention has a mechanical loss tangent (tan) at body temperature (T ° C.).
δ T ) is at least 0.5, preferably at least 1.
0, more preferably at least 2.0. t
If Anderuta T is less than 0.5, always giving tightness to the surrounding tissue in the body insertion state for too hard, i.e. give rise to discomfort, also when moving muscle portion thereof, if painful Because there is even.
【0012】本発明の医療用チューブは、体温における
横弾性率(GT ) が1〜1000MPa、好ましくは1
0〜500MPa、より好ましくは20〜100MPa
である。当該医療用チューブのGT が1000MPaを
越えれば、当該チューブ自体が硬すぎるために、体内挿
入状態において常に周囲の組織にツッパリ感を与え、即
ち違和感を生ぜしめる等のtanδTが、0.5未満で
ある場合と同様の欠点がある。一方、GT が1MPa未
満のものでは、機械的強度が低いために通常の医療用チ
ューブにあっては、チューブは体内圧力で圧潰するとい
う問題がある。特に、静脈留置カテーテル(以下、単に
カニューレという)、EDカテーテル等は長時間体内に
留置させところから、極力違和感を少なくすることが要
求される。The medical tube of the present invention has a transverse elastic modulus (G T ) at body temperature of 1 to 1000 MPa, preferably 1 to 1000 MPa.
0 to 500 MPa, more preferably 20 to 100 MPa
It is. If G T of the medical tube exceeds the 1000 MPa, for the tube itself is too hard, the tan [delta T, such as always giving tightness to the surrounding tissue, i.e. give rise to discomfort in the body insertion state, 0.5 There are similar disadvantages as being less than. On the other hand, those G T is less than 1 MPa, In the conventional medical tubes for mechanical strength is low, the tube is a problem of collapse in the body pressures. In particular, since a vein indwelling catheter (hereinafter, simply referred to as a cannula), an ED catheter, and the like are left in the body for a long time, it is required to minimize discomfort.
【0013】本発明において上記の2物性は、以下に示
す方法にて測定した値である。 tanδ:動的損失弾性率Aと動的貯蔵弾性率Bとをそ
れぞれ測定し、A/Bを求めた値である。 GT :測定機としてRMS800(Rheometrics, Inc.)
を使用し、周波数1.0Hzのねじり振動を加える条件
のもとで測定した値である。In the present invention, the above two physical properties are values measured by the following methods. tan δ: A value obtained by measuring the dynamic loss elastic modulus A and the dynamic storage elastic modulus B, and calculating A / B. G T: as a measuring instrument RMS800 (Rheometrics, Inc.)
Is a value measured under conditions of applying torsional vibration at a frequency of 1.0 Hz.
【0014】また、好ましい態様として、有機高分子の
吸水率が5重量%以下、好ましくは2重量%以下、特に
好ましくは1.5重量%以下のものが推奨される。吸水
率が5重量%を越えると、チューブの膨潤により周囲の
組織を圧迫することとなり、違和感を生じさせる場合が
多い。本発明の医療用チューブをカニューレ、EDカテ
ーテル等として適用する場合は、特にその傾向が強い。
吸水率は、本発明の医療用チューブを適用する動物の体
温(例えば、ヒト体温である36.5℃)において測定
したものであり、試料を体温に相当する温度の水に24
時間浸漬して吸水状態としたものを150℃×30分乾
燥し、析出する水分をカールフィッシャー水分測定装置
にて定量することによって測定したものである。In a preferred embodiment, an organic polymer having a water absorption of 5% by weight or less, preferably 2% by weight or less, particularly preferably 1.5% by weight or less is recommended. When the water absorption exceeds 5% by weight, the surrounding tissue is pressed by the swelling of the tube, which often causes a sense of discomfort. This tendency is particularly strong when the medical tube of the present invention is applied as a cannula, an ED catheter or the like.
The water absorption is measured at the body temperature of an animal to which the medical tube of the present invention is applied (for example, 36.5 ° C., which is a human body temperature).
It was measured by immersing it in a water absorbing state for a period of time and drying it at 150 ° C. for 30 minutes, and quantifying the precipitated water with a Karl Fischer moisture meter.
【0015】本発明の医療用チューブは、チューブを体
内に挿入した状態、換言すれば体温において上記の柔軟
性を有し、かつ挿入前の室温あるいは人工的に用意した
低温度(例えば10−15℃)において充分な剛直性を
有することが刺通抵抗の観点から好ましい。The medical tube of the present invention has the above-mentioned flexibility in a state where the tube is inserted into the body, in other words, at the body temperature, and has a room temperature before insertion or a low temperature artificially prepared (for example, 10 to 15). (° C) is preferred from the viewpoint of piercing resistance.
【0016】また、本発明を、例えば図1に示す如き、
金属性内針(例えば、ステンレス製内針)を有するカニ
ューレに適応する場合、体内に挿入する直前における剛
直性が不足すると、挿入の際にカニューレが内針からめ
くれて刺通抵抗を大きく増大させる問題、さらには場合
によっては患者に対して激痛を生じさせるという問題が
あるが、このめくれを防止する観点からも充分な剛直性
を有することが好ましい。また、EDカテーテルは、口
または鼻から喉、食道、胃を経由して、十二指腸に留置
するものであるから、充分な剛直性を有することが好ま
しい。具体的には、GT-10/GT (ここにGT-10は体温
より10℃低い温度における横弾性率)が少なくとも
2、好ましくは少なくとも3、特に好ましくは少なくと
も8であることが望ましい。Further, the present invention is, for example, as shown in FIG.
When applying to a cannula having a metallic inner needle (for example, a stainless steel inner needle), if the rigidity immediately before insertion into the body is insufficient, the cannula is turned up from the inner needle at the time of insertion and greatly increases the penetration resistance. Although there is a problem, and in some cases, a problem of causing severe pain to the patient, it is preferable to have sufficient rigidity also from the viewpoint of preventing this turning. Further, since the ED catheter is placed in the duodenum from the mouth or nose via the throat, esophagus and stomach, it is preferable that the ED catheter has sufficient rigidity. Specifically, G T-10 / G T ( here G T-10 is modulus of transverse elasticity at 10 ° C. below body temperature) of at least 2, preferably at least 3, particularly preferably at least 8 .
【0017】本発明において有機高分子としては、体温
における機械的損失正接が少なくとも0.5であり、か
つ体温における横弾性率が1〜1000MPaであると
いう条件を満足するものであれば、挿入対象となる動物
に対して無害である限りいかなる材料のものでもよい。
具体的には、ポリウレタン、スチレン−ブタジエン共重
合体、アクリロニトリル−ブタジエン共重合体等が好ま
しく、特にポリウレタンが好ましい。In the present invention, as the organic polymer, if it satisfies the condition that the mechanical loss tangent at body temperature is at least 0.5 and the transverse elastic modulus at body temperature is 1 to 1000 MPa, Any material may be used as long as it is harmless to the animal.
Specifically, polyurethane, styrene-butadiene copolymer, acrylonitrile-butadiene copolymer and the like are preferable, and polyurethane is particularly preferable.
【0018】ポリウレタンを製造するのに使用されるイ
ソシアネート成分としては、通常ポリウレタンに使用さ
れるものであれば特に制限はなく、例えば2,4−また
は2,6−トリレンジイソシアネート、4,4’−ジフ
ェニルメタンジイソシアネート、ヘキサメチレンジイソ
シアネート、m−またはp−フェニレンジイソシアネー
ト、イソホロンジイソシアネート等が例示され、これら
単独または2種以上の組み合わせにて使用される。イソ
シアネート成分としては、特に4,4’−ジフェニルメ
タンジイソシアネートが好ましい。The isocyanate component used for producing the polyurethane is not particularly limited as long as it is usually used for polyurethanes. For example, 2,4- or 2,6-tolylene diisocyanate, 4,4 ' -Diphenylmethane diisocyanate, hexamethylene diisocyanate, m- or p-phenylene diisocyanate, isophorone diisocyanate, and the like, and these can be used alone or in combination of two or more. As the isocyanate component, 4,4′-diphenylmethane diisocyanate is particularly preferred.
【0019】またポリオール成分としては、1分子中に
少なくとも2個以上の活性水素、特に水酸基を有するも
のが用いられ、例えばジオールやトリオール等の多価ア
ルコール、脂肪族アミン、芳香族アミン等を開始剤と
し、これにアルキレンオキサイドを付加して製造される
ポリオキシアルキレンポリオール、酸とアルコールの縮
合により製造されるポリエステルポリオール、あるいは
ポリテトラメチレングリコール、ポリブタジエンポリオ
ール、ポリプロピレングリコール、ポリ1,4−ブチレ
ングリコールアジペート、ポリエチレングリコールアジ
ペート、ポリテトラメチレングリコール、ポリエチレン
グリコール、ビスフェノール−A+プロピレンオキサイ
ド、特に好ましいものとしてビスフェノール−A+プロ
ピレンオキサイド等が使用される。ポリオールの好まし
い重量平均分子量は200─2000程度である。As the polyol component, one having at least two or more active hydrogens in one molecule, particularly a hydroxyl group, is used. For example, polyhydric alcohols such as diols and triols, aliphatic amines, aromatic amines and the like are used. Agent, a polyoxyalkylene polyol produced by adding an alkylene oxide thereto, a polyester polyol produced by condensing an acid and an alcohol, or polytetramethylene glycol, polybutadiene polyol, polypropylene glycol, poly-1,4-butylene glycol Adipate, polyethylene glycol adipate, polytetramethylene glycol, polyethylene glycol, bisphenol-A + propylene oxide, particularly preferably bisphenol-A + propylene oxide It is used. The preferred weight average molecular weight of the polyol is about 200-2000.
【0020】鎖延長剤としては、エチレングリコール、
1,4−ブタンジオール、ジエチレングリコール等のグ
リコール、ジエタノールアミン、トリエタノールアミ
ン、トリレンジアミン、ヘキサメチレンジアミン等のア
ミン類、トリメチロールプロパンのTDI(トリレンジ
イソシアネート)アダクト、トリフェニルメタントリイ
ソシアネート、ビス(2−ハイドロキシエチル)ハイド
ロキノン、ビスフェノール−A+エチレンオキサイド、
ビスフェノール−A+プロピレンオキサイド等のポリイ
ソシアネート等が挙げられる。鎖延長剤としては、特に
1,4−ブタンジオールが好ましい。As the chain extender, ethylene glycol,
Glycols such as 1,4-butanediol and diethylene glycol, amines such as diethanolamine, triethanolamine, tolylenediamine and hexamethylenediamine, TDI (tolylenediisocyanate) adduct of trimethylolpropane, triphenylmethane triisocyanate, bis ( 2-hydroxyethyl) hydroquinone, bisphenol-A + ethylene oxide,
Examples include polyisocyanates such as bisphenol-A + propylene oxide. As the chain extender, 1,4-butanediol is particularly preferred.
【0021】これらイソシアネート成分、鎖延長剤およ
びポリオール成分のモル比は、1.5〜3:0.5〜
2:1、好ましくは1.8〜2.5:0.8〜1.5:
1であり、カニューレ、EDカテーテル共により好まし
くは1.9〜2.2:0.9〜1.2:1である。The molar ratio of the isocyanate component, the chain extender and the polyol component is from 1.5 to 3: 0.5 to
2: 1, preferably 1.8-2.5: 0.8-1.5:
1, more preferably 1.9 to 2.2: 0.9 to 1.2: 1 for both the cannula and the ED catheter.
【0022】また、必要に応じて反応を促進する為に触
媒が使用される。触媒としてはトリエチルアミン、テト
ラメチルヘキサメチレンジアミン、トリレンジアミン等
の第3級アミン類またはスタナスオクチレート、スタナ
スオレエート、ジブチル錫ジラウレートの如き錫系触媒
に代表される金属触媒があり、これらはおのおの単独あ
るいは混合して使用される。Further, a catalyst is used if necessary to accelerate the reaction. Examples of the catalyst include tertiary amines such as triethylamine, tetramethylhexamethylenediamine, and tolylenediamine, and metal catalysts represented by tin catalysts such as stannas octylate, stannas oleate, and dibutyltin dilaurate. Are used alone or in combination.
【0023】上記イソシアネート、ポリオール、鎖延長
剤及び必要に応じて触媒を用いてウレタンの合成を行
う。合成方法は、たとえば特開昭61−293214号
公報、特開昭63−244341号公報等に開示されて
いる方法を採用することができる。Urethane is synthesized using the above-mentioned isocyanate, polyol, chain extender and, if necessary, a catalyst. As the synthesis method, for example, the methods disclosed in JP-A-61-293214 and JP-A-63-244341 can be adopted.
【0024】本発明の医療用チューブは、上記の如き材
料を使用して、自体既知の手段、例えば押出成形等によ
って作成することができる。The medical tube of the present invention can be produced by using a material as described above by a means known per se, for example, extrusion molding.
【0025】本発明の医療用チューブの外径及び肉厚
は、例えばカニューレにおいては、外径0.5mm〜
2.8mm、肉厚0.05mm〜0.4mm、好ましく
は外径0.6mm〜2.3mm、肉厚0.1mm〜0.
3mmである。また、EDカテーテルにおいては外径
1.0mm〜4.0mm、肉厚0.1mm〜1.2m
m、好ましくは外径1.6mm〜3.5mm、肉厚0.
2mm〜0.7mmである。The outer diameter and wall thickness of the medical tube of the present invention may be, for example, 0.5 mm or more for a cannula.
2.8 mm, wall thickness 0.05 mm to 0.4 mm, preferably outer diameter 0.6 mm to 2.3 mm, wall thickness 0.1 mm to 0.4 mm.
3 mm. In the ED catheter, the outer diameter is 1.0 mm to 4.0 mm, and the wall thickness is 0.1 mm to 1.2 m.
m, preferably an outer diameter of 1.6 mm to 3.5 mm, and a wall thickness of 0.1 mm.
It is 2 mm to 0.7 mm.
【0026】[0026]
【実施例】以下、実施例により本発明を具体的に説明す
るが、本発明はこれらに何ら限定されるものではない。EXAMPLES The present invention will now be described specifically with reference to examples, but the present invention is not limited to these examples.
【0027】実施例1〜10・比較例1〜5 カニューレ構成用の有機高分子として、表1に示す種々
のものを用いて、押出成型によってカニューレを製造
し、これにSUS304製の内針を挿入したものを製造
した。表1には材料の化学種並びに36.5℃および2
6.5℃において測定した諸物性を示す。表示する材料
のうち材料1〜10はそれぞれ本発明の実施例1〜10
のカニューレで使用対象とするもの、材料21〜25は
それぞれ比較例1〜5で使用対象とするものである。な
お、表1に示したポリウレタンについては、使用したイ
ソシアナート成分、ポリオール成分および鎖延長剤の種
類と量(モル比)とを表2に示す。Examples 1 to 10 and Comparative Examples 1 to 5 Cannulae were produced by extrusion using various organic polymers shown in Table 1 as constituents of the cannula, and an inner needle made of SUS304 was added thereto. The insert was manufactured. Table 1 shows the chemical species of the materials and 36.5 ° C. and 2
The various physical properties measured at 6.5 ° C. are shown. Of the materials to be displayed, materials 1 to 10 are Examples 1 to 10 of the present invention, respectively.
The materials 21 to 25 to be used in the cannula are materials to be used in Comparative Examples 1 to 5, respectively. Table 2 shows the types and amounts (molar ratios) of the isocyanate component, the polyol component, and the chain extender used for the polyurethanes shown in Table 1.
【0028】[0028]
【表1】 [Table 1]
【0029】[0029]
【表2】 [Table 2]
【0030】試験例1 本発明挿入用チューブの違和感の有無を調べた。図1
は、本試験に使用したカニューレ1の断面図である。即
ち、実施例1〜10および比較例1〜5に記載の材料よ
りなり、外径1.32mm、内径0.96mm、肉厚0.1
8mm、長さ70mmの留置部4およびポリプロピレンより
なるハブ2を有するカニューレを、通常の押出成型法
(芯線使用)を経て製造し、これに先端部が鋭利となっ
たSUS304製の内針3を挿入したものを作成した。
なお、当該留置部はその先端部がテーパ状に細くなって
おり、先端部の肉厚は、中央部のほぼ半分程度となって
いる。Test Example 1 The insertion tube of the present invention was examined for any uncomfortable feeling. FIG.
FIG. 3 is a cross-sectional view of the cannula 1 used in this test. That is, it is made of the materials described in Examples 1 to 10 and Comparative Examples 1 to 5, and has an outer diameter of 1.32 mm, an inner diameter of 0.96 mm, and a wall thickness of 0.1.
A cannula having an indwelling part 4 having a length of 8 mm and a length of 70 mm and a hub 2 made of polypropylene is manufactured through a normal extrusion molding method (using a core wire), and an inner needle 3 made of SUS304 having a sharp tip is formed thereon. Created what was inserted.
The tip of the indwelling portion is tapered, and the thickness of the tip is approximately half that of the center.
【0031】上記の如くして作成した各々のカニューレ
につき、ヒトに適用した場合の違和感を以下の方法にて
試験し、その結果を表3に示した。Each cannula prepared as described above was tested for discomfort when applied to humans by the following method. The results are shown in Table 3.
【0032】(試験方法)それぞれ10名の健常人に対
して、左腕の尺側皮静脈に各カニューレを挿入し、血液
が流出するのを確かめてから内針3のみを引き抜き、ハ
ブ側より血液が流出することを確かめ、3分後にカニュ
ーレを動かして違和感の有無を調べた。(Test Method) For each of ten healthy persons, each cannula was inserted into the ulnar cutaneous vein of the left arm, and it was confirmed that blood had flowed out. Then, only the inner needle 3 was withdrawn, and blood was drawn from the hub side. 3 minutes later, the cannula was moved to check for uncomfortable feeling.
【0033】(判定方法)次の判定規準によって各人の
違和感を得点で表し、10人の得点の平均値を求めた。(Judgment method) The feeling of discomfort of each person was represented by a score according to the following criteria, and the average value of the scores of 10 people was determined.
【0034】5点:ほとんど違和感なし 4点:多少違和感あり 3点:違和感あり 2点:比較的強い違和感あり 1点:強い違和感あり5 points: almost no discomfort 4 points: some discomfort 3 points: discomfort 2 points: relatively strong discomfort 1 point: strong discomfort
【0035】試験例2 試験例1で使用した各カニューレについて、刺通抵抗お
よびめくれ現象の有無を調べた。Test Example 2 For each cannula used in Test Example 1, the puncture resistance and the presence or absence of the turning-up phenomenon were examined.
【0036】(1) めくれ現象評価法 カニューレを100mm/minの刺通速度で薬包紙(白パラ
フィン紙、中サイズ:105mm×105mm)6枚に穿刺
して、その際のカニューレ先端のめくれの有無を目視に
より判定し、比較例のものと比較した。その結果は表3
に示した。(1) Method of Evaluating the Turn-Up Phenomenon The cannula was pierced into six pieces of medicine packaging paper (white paraffin paper, medium size: 105 mm × 105 mm) at a penetration speed of 100 mm / min. It was visually determined and compared with that of the comparative example. Table 3 shows the results.
It was shown to.
【0037】(2) 刺通抵抗評価法 試験例1で使用した各々のカニューレを、測定装置とし
て引張試験機オートグラフ、島津S500Dを用い、1
00mm/minの刺通速度でゴム板(NRJISK6301
厚さ1.5mm、ショアA硬度30)に穿刺したときの
カニューレ先端部に続く平行部の刺通抵抗(gf)を測
定し、比較例のものと比較した。その結果は表3に示し
た。(2) Penetration Resistance Evaluation Method Each of the cannulas used in Test Example 1 was used as a measuring device by using a tensile tester Autograph, Shimadzu S500D.
A rubber plate (NRJISK6301) with a penetration speed of 00 mm / min
The penetration resistance (gf) of the parallel portion following the tip of the cannula when piercing to a thickness of 1.5 mm and a Shore A hardness of 30) was measured and compared with that of the comparative example. The results are shown in Table 3.
【0038】[0038]
【表3】 [Table 3]
【0039】実施例11〜12・比較例6〜7 実施例8に記載の材料よりなり、外径3.5mm、内径
3.0mm、肉厚0.25、長さ1200mmのチューブ
(実施例11)および実施例9に記載の材料よりなり、
外径3.5mm、内径3.0mm、肉厚0.25、長さ12
00mmのチューブ(実施例12)を通常の押出成形(チ
ューブ成形)によって作成し、その片端に入口部を設
け、他端には吐出部およびそれに続く部位に0.5gの
重りを設けて、EDカテーテルを作成した。また、比較
としてエチレンビニルアセテート共重合体(EVA)製
(比較例6)およびシリコン樹脂製(比較例7)の外径
3.5mm、径3.0mm、肉厚0.25、長さ1200mm
のチューブよりなる上記と同様のEDカテーテルを作成
した。Examples 11 to 12 and Comparative Examples 6 and 7 A tube made of the material described in Example 8 and having an outer diameter of 3.5 mm, an inner diameter of 3.0 mm, a wall thickness of 0.25, and a length of 1200 mm (Example 11) ) And the material described in Example 9;
Outer diameter 3.5mm, inner diameter 3.0mm, wall thickness 0.25, length 12
A 00 mm tube (Example 12) was prepared by ordinary extrusion molding (tube molding), an inlet was provided at one end, and a 0.5 g weight was provided at the other end at a discharge part and a part following the discharge part. A catheter was made. For comparison, an outer diameter of 3.5 mm, a diameter of 3.0 mm, a wall thickness of 0.25, and a length of 1200 mm made of ethylene vinyl acetate copolymer (EVA) (Comparative Example 6) and made of silicone resin (Comparative Example 7).
An ED catheter similar to the one described above was prepared.
【0040】試験例3 本発明挿入用チューブの、挿入性、挿入時以後の痛みお
よび違和感の有無を調べた。Test Example 3 The insertion tube of the present invention was examined for insertability, pain after insertion, and for any uncomfortable feeling.
【0041】(試験方法)上記の如くして作成した各々
のEDカテーテルを、それぞれ6名の健常人の鼻から
喉、食道、胃を経由して、十二指腸に24時間留置し、
その挿入性、留置時における痛みおよび違和感を調べ、
その結果を表4に示した。(Test Method) Each of the ED catheters prepared as described above was placed in the duodenum for 24 hours through the nose, throat, esophagus and stomach of six healthy persons, respectively.
Investigate its insertion, pain and discomfort at the time of placement,
Table 4 shows the results.
【0042】[0042]
【表4】 [Table 4]
【0043】なお、本試験例で使用したEVAおよびシ
リコン樹脂の26.5℃および36.5℃における特性
は、次の通りである。The characteristics of the EVA and the silicone resin used in this test example at 26.5 ° C. and 36.5 ° C. are as follows.
【0044】 EVA シリコン樹脂 tan δT : 5×10-2 3×10-2 tan δT-10: 5×10-2 3×10-2 GT : 22MPa 10.5MPa GT-10: 25MPa 10.5MPa GT-10/GT 1.1 1.0 吸水率: 0.4wt% 0.1wt% EVA silicone resin tan δ T : 5 × 10 -2 3 × 10 -2 tan δ T-10 : 5 × 10 -2 3 × 10 -2 G T : 22 MPa 10.5 MPa G T-10 : 25 MPa 10 .5MPa G T-10 / G T 1.1 1.0 water absorption: 0.4 wt% 0.1 wt%
【0045】[0045]
【発明の効果】以上の試験結果から明らかな様に、本発
明の医療用チューブは、動物体内への挿入時には優れた
剛直性を有するので容易に体内への挿入が可能であり、
また動物体内に挿入した状態で充分な耐圧潰性、耐座屈
性を示しながら、しかも従来品と比較して柔軟であるの
で長時間体内に留置させても違和感が少ない。As is clear from the above test results, the medical tube of the present invention has excellent rigidity when inserted into an animal body, so that it can be easily inserted into the body.
In addition, while exhibiting sufficient pressure crush resistance and buckling resistance when inserted into an animal body, it is more flexible than conventional products, so that even if it is left in the body for a long time, there is little discomfort.
【0046】特に吸水率が5重量%以下のものは、従来
の親水性が高いチューブのように、血管内等で膨潤する
ことがないので、より違和感が少なく使用することがで
きるという利点を有する。In particular, those having a water absorption of 5% by weight or less do not swell in blood vessels and the like unlike conventional tubes having high hydrophilicity, and thus have an advantage that they can be used with less discomfort. .
【図1】本発明の試験例で使用されたカニューレの断面
図である。FIG. 1 is a cross-sectional view of a cannula used in a test example of the present invention.
【符号の説明】 1 カニューレ 2 ハブ 3 内針 4 留置部 5 プラグ[Description of Signs] 1 cannula 2 hub 3 inner needle 4 indwelling part 5 plug
───────────────────────────────────────────────────── フロントページの続き (72)発明者 松本 孝 大阪市北区本庄西三丁目9番3号 株式 会社ニッショー内 (72)発明者 辻川 肇 大阪市北区本庄西三丁目9番3号 株式 会社ニッショー内 (72)発明者 林 俊一 名古屋市中村区岩塚町字高道1番地 三 菱重工業株式会社名古屋研究所内 (72)発明者 近藤 悟 名古屋市中村区岩塚町字高道1番地 三 菱重工業株式会社名古屋研究所内 (72)発明者 内海 厚 兵庫県伊丹市池尻4丁目3番地 三菱電 線工業株式会社伊丹製作所内 (72)発明者 開出 保 兵庫県尼崎市東向島西之町8番地 三菱 電線工業株式会社内 (58)調査した分野(Int.Cl.6,DB名) A61L 29/00──────────────────────────────────────────────────続 き Continuing on the front page (72) Takashi Matsumoto 3-9-3, Honjo-Nishi, Kita-ku, Osaka-shi Nissha Corporation (72) Inventor Hajime Tsujikawa 3-9-1, Honjo-Nishi, Kita-ku, Osaka (72) Inventor: Shunichi Hayashi, Nagoya City, Nagoya-shi, Iwatsuka-cho, Takamichi 1, Nagoya Research Laboratories Co., Ltd. (72) Inventor Satoru Kondo, Nagoya, Nakamura-ku, Iwatsuka-cho, Takamichi, 1-3-1 Inside Nagoya Research Laboratories Co., Ltd. (72) Atsushi Utsumi 4-3-1 Ikejiri, Itami-shi, Hyogo Mitsubishi Electric Wire Industry Co., Ltd.Itami Seisakusho Co., Ltd. (58) Investigated field (Int. Cl. 6 , DB name) A61L 29/00
Claims (10)
も0.5でかつ体温における横弾性率が1〜1000M
Paである有機高分子よりなることを特徴とする医療用
チューブ。1. A mechanical loss tangent at body temperature of at least 0.5 and a transverse elastic modulus at body temperature of 1 to 1000 M
A medical tube comprising an organic polymer of Pa.
性率が、体温における横弾性率の少なくも2倍である有
機高分子よりなることを特徴とする請求項1記載の医療
用チューブ。2. The medical tube according to claim 1, wherein the transverse elastic modulus at a temperature lower by 10 ° C. than the body temperature is made of an organic polymer having a transverse elastic modulus at least twice the body temperature.
量%以下である請求項1記載の医療用チューブ。3. The medical tube according to claim 1, wherein the water absorption of the organic polymer at body temperature is 5% by weight or less.
項1記載の医療用チューブ。4. The medical tube according to claim 1, wherein the organic polymer is polyurethane.
タンまたはポリエステル系ポリウレタンである請求項4
記載の医療用チューブ。5. The polyurethane according to claim 4, wherein the polyurethane is a polyether polyurethane or a polyester polyurethane.
The medical tube as described.
分、鎖延長剤およびポリオール成分のモル比が1.5〜
3:0.5〜2:1である請求項4記載の医療用チュー
ブ。6. The polyurethane according to claim 1, wherein the molar ratio of the isocyanate component, the chain extender and the polyol component is from 1.5 to 1.5.
The medical tube according to claim 4, wherein the ratio is 3: 0.5 to 2: 1.
分、鎖延長剤およびポリオール成分のモル比が1.8〜
2.5:0.8〜1.5:1である請求項6記載の医療
用チューブ。7. The polyurethane according to claim 1, wherein the molar ratio of the isocyanate component, the chain extender and the polyol component is from 1.8 to 1.8.
The medical tube according to claim 6, wherein the ratio is 2.5: 0.8 to 1.5: 1.
分、鎖延長剤およびポリオール成分のモル比が1.9〜
2.2:0.9〜1.2:1である請求項7記載の医療
用チューブ。8. The polyurethane according to claim 1, wherein the molar ratio of the isocyanate component, the chain extender, and the polyol component is from 1.9 to 1.9.
The medical tube according to claim 7, wherein the ratio is 2.2: 0.9 to 1.2: 1.
の医療用チューブ。9. The medical tube according to claim 1, which is an indwelling venous catheter.
載の医療用チューブ。10. The medical tube according to claim 1, which is an enteral feeding catheter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4084702A JP2759305B2 (en) | 1991-03-08 | 1992-03-06 | Medical tubing |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6934491 | 1991-03-08 | ||
JP3-69344 | 1991-03-08 | ||
JP4084702A JP2759305B2 (en) | 1991-03-08 | 1992-03-06 | Medical tubing |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0584293A JPH0584293A (en) | 1993-04-06 |
JP2759305B2 true JP2759305B2 (en) | 1998-05-28 |
Family
ID=26410542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4084702A Expired - Lifetime JP2759305B2 (en) | 1991-03-08 | 1992-03-06 | Medical tubing |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2759305B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4570707B2 (en) * | 1998-06-02 | 2010-10-27 | テルモ株式会社 | Indwelling catheter |
JP4570708B2 (en) * | 1998-06-02 | 2010-10-27 | テルモ株式会社 | Indwelling catheter made of polyurethane resin containing multiple polyglycols with different molecular weights |
KR100415256B1 (en) * | 2002-01-18 | 2004-01-16 | 씨제이 주식회사 | Blood-collecting means and blood-collecting method using the blood-collecting means |
CA2514426C (en) | 2003-01-27 | 2008-09-16 | Mitsui Chemicals, Inc. | Propylene polymer composition and use thereof |
EP1820521B1 (en) | 2004-11-26 | 2011-12-28 | Mitsui Chemicals, Inc. | Medical tube |
US7872068B2 (en) * | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
CN104203296B (en) * | 2012-03-14 | 2017-06-09 | 电化株式会社 | Medical multilayer pipe |
CN109996568A (en) * | 2017-03-08 | 2019-07-09 | 泰尔茂株式会社 | Inlying catheter |
-
1992
- 1992-03-06 JP JP4084702A patent/JP2759305B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH0584293A (en) | 1993-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6193699B1 (en) | Medical tube | |
US5336205A (en) | Flow directed catheter | |
EP0289218A2 (en) | A flexible composite intubation tube | |
JPH04221571A (en) | Catheter tube with in vivo softening property controlled | |
US20020018866A1 (en) | Polyether block amide catheter balloons | |
JP2625354B2 (en) | Thermoplastic polyurethane blend | |
JP2001524009A (en) | Systems and methods for promoting tissue growth | |
WO2006042157A1 (en) | A flexible tip | |
JP7100015B2 (en) | Indwelling catheter | |
JP2759305B2 (en) | Medical tubing | |
JPH04507054A (en) | Implantable catheters made of materials with high cold flow | |
KR20210053546A (en) | Levin tube having detachable function | |
JPH01121064A (en) | Catheter | |
Shah | Catheterization | |
JP4174277B2 (en) | Dilatation balloon catheter | |
JPS63277062A (en) | Blood vessel contrast catheter | |
JP2809337B2 (en) | Catheter tube with controlled softening in vivo | |
JP3462903B2 (en) | Medical device with lubricious surface when wet | |
JPH1133107A (en) | Indwelling catheter | |
Hirsch et al. | Design and production of enteral feeding tubes | |
JP2004222810A (en) | Extradural anesthesia catheter | |
CN112156333A (en) | Ureter expansion sacculus | |
JP3580843B2 (en) | Low friction medical device and method of manufacturing the same | |
JP2001046492A (en) | Medical tube | |
CN106964053A (en) | A kind of J-type conduit of high-elastic disintegratable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19980127 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080320 Year of fee payment: 10 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080320 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090320 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100320 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110320 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110320 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120320 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term |